Affymetrix Applies LION's Integration Platform SRS to Internal and External Solutions
SRS Expected to Become the Industry Standard for Data Integration
HEIDELBERG, Germany, May 17, 2001 /PRNewswire via COMTEX/ -- LION bioscience AG
(Neuer Markt: LIO, WKN 504 350, Nasdaq: LEON) today announced that it has
granted a license for LION's data integration system SRS to Affymetrix, Inc.
(Nasdaq: AFFX) to build a web portal for its customers as well as for internal
use. The web portal will supply detailed information relating to Affymetrix's
GeneChip(R) probe arrays and related products. This new application of SRS as a
web portal follows its prominent application for the Celera Discovery
System(TM)(CDS) and further demonstrates the outstanding position of LION's SRS
system in supplying scientific data and information. SRS integrates diverse data
through one interface and is the basis for LION's enterprise-wide R&D knowledge
management solutions i-biology(R).
"With LION's proven success in the market and LION's expertise with portals
based on SRS, we can now provide our customers with a state-of-the-art system to
access supporting information for their research," said David Craford, Vice
President of Marketing, Instrumentation and Informatics. "Affymetrix's new web
portal will offer our customers added value and enable them to more rapidly
understand biological functions of genes analyzed using our expression arrays,
and thus resulting in the acceleration of new discoveries."
LION's SRS system integrates more than 400 diverse databases. It is currently
used by more than 50 commercial customers and more than 100 academic
institutions worldwide. SRS is at the heart of LION's Life Science Informatics
solutions, integrating diverse data throughout the entire R&D process.
Affymetrix's portal is expected to provide access to a wide range of biological
data including genomes, genes, transcripts, proteins, and literature annotation.
SRS also serves as a web portal for the Celera Discovery System(TM) (CDS)
established in March 2000, which allows rapid access to drosophila and human
genome data; the web portal of Scientific World, established in January 2000
supplies data from scientific literature via the Internet.
"Affymetrix's use of the SRS technology for its web portal and its own research
reinforces our leading position and increases our visibility in the rapidly
expanding market of expression profiling," said Dr. Jan Mous, Chief Scientific
Officer of LION bioscience. "In addition to Celera's CDS and other applications,
the Affymetrix portal is yet another commercial application of the unique
integration capabilities of SRS for rapid information access. This supports
LION's outstanding position in the market and strengthens the position of SRS as
the standard integration platform for diverse data in the market."
About LION bioscience AG:
LION bioscience (http://www.lionbioscience.com) provides proven information and
knowledge management solutions to significantly improve life science R&D
performance and productivity. These solutions integrate all R&D disciplines,
spanning from genetics to early and late discovery through clinical trials. LION
offers these solutions via two primary lines of business:
-- i-biology(R): the installation and implementation of enterprise-wide
horizontal information and knowledge management solutions as part of
LION's Life Science Informatics (LSI(TM)) line of business; and
-- Integrated Drug Discovery and Diagnostics (iD3(TM)): application of
i-biology(R) to LION's internal drug discovery program with the goal to
out-license specific databases, polymorphism marker panels, and
validated targets and leads.
Founded in 1997, LION, together with its consolidated subsidiaries, has more
than 440 employees, with headquarters in Heidelberg, Germany, and subsidiaries
in Cambridge, UK, Cambridge, MA, USA and San Diego, CA, USA. To date, LION has
established partnerships with leading life science companies, including Aventis,
Bayer, Boehringer Ingelheim, Celera, DuPont, Glaxo Wellcome, GMD, Janssen, Merck
Inc., Nestle, Novartis, Paradigm Genetics, Pharmacia & Upjohn, Roche, SmithKline
Beecham, Sumitomo Pharmaceuticals and Tripos.
All statements in this press release that are not historical are forward-looking
statements within the meaning of the U.S. securities laws. Such statements are
based on current expectations that are subject to risks and uncertainties.
Actual results may vary materially from those projected because of factors such
as uncertainties relating to technologies, product development, or
manufacturing, market acceptance, cost or pricing of LION's products, dependence
on collaborations and partners, regulatory approvals, competition, intellectual
property of others, or patent protection and litigation. These and other risk
factors are discussed in LION's Registration Statement on Form F-4 declared
effective by the SEC on February 9, 2001. LION expressly disclaims any
obligation or undertaking to release publicly any updates, revisions or
corrections to any forward-looking statements or historical information
contained herein.
LION bioscience(R) and i-biology(R) are either registered trademarks of LION
bioscience AG in the United States and/or other countries, or LION bioscience AG
has pending applications for these trademarks in the United States and/or other
countries. The names of actual companies and products mentioned herein may be
the trademark of the respective owners. Trega Biosciences, Inc. has a pending
trademark application for iDEA(TM) in the United States. Trega(R) is a
registered trademark of Trega Biosciences, Inc.
MAKE YOUR OPINION COUNT - Click Here
tbutton.prnewswire.com
SOURCE LION bioscience AG
CONTACT: Dr. Andrea Kreisselmeier, Director Corporate Marketing &
Communications of LION bioscience, +49-0-6221-4038-265,
andrea.kreisselmeier@lionbioscience.com; or Matthew Scampoli of Noonan-Russo
Communications, 212-696-4455, ext. 243, m.scampoli@noonanrusso.com, for LION
bioscience AG
URL: lionbioscience.com |
